Matthew Yates,
Research Scientist
Matthew Yates obtained his BS in chemistry from Vanderbilt University in
1994 where his studies involved the synthesis of clozapine analogs. He
earned his PhD from Rice University in 1999, where he focused on new
methodology and natural product synthesis. During his tenure at Rice he
had the opportunity to conduct 2 years of his research in Lyon, France.
Matt began his industrial career as a process chemist at DuPont Merck,
which through a series of transitions became a part of BMS. While at
DuPont/BMS he led and supported numerous projects focused on HIV and
inflammation. Matt joined Eli Lilly and company in 2002 where he has led
projects across the spectrum from pre-clinical to post launch, and has made
contributions in both drug substance and drug product. His current role at
Lilly involves the design and selection of the preferred chemical
manufacturing route for complex small molecule pharmaceutical agents.
Additionally, he has played a key role in Lilly’s interactions with the
academic community through the Academic Contacts Committee, the Lilly
Grantee program, and several formal academic collaborations.
|
|
|
